A Vision for the Future: Improving Early Detection and Treatment of Diabetic Retinopathy in Rural and Underserved Settings

Released On
February 26, 2021

Expires On
February 26, 2022

Media Type

Completion Time
60 minutes

Endocrinology, Ophthalmology, Primary Care


Scroll to the Bottom of this Information to Begin this Course

This activity is jointly provided by Rural Medical Education (RME) Collaborative and Postgraduate Institute for Medicine.

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)
  • Nurses — 1.0 Nursing Contact Hours

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity is designed to meet the educational needs of primary care clinicians, registered nurses, and advanced practice registered nurses who care for patients from rural and underserved areas.

Statement of Need/Program Overview

Diabetic retinopathy affects an estimated 7.7 million Americans and is the most common cause of blindness in working-age adults. Since the prevalence of diabetes is higher in rural versus urban communities, rural residents are at increased risk for this complication. Rural-specific barriers, including transportation issues, distance to health clinics, physician shortages, and limited exposure to diabetes education, result in further disparities in care. In this activity, expert faculty will discuss guideline recommendations for screening patients with diabetes and novel treatment options for diabetic retinopathy. Strategies to improve care in rural and underserved settings will also be reviewed.

This enduring activity is a recorded session from the 2nd Annual Rural Health Clinical Congress that took place on November 21, 2020.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Implement strategies to improve screening for diabetic retinopathy
  • Evaluate recent clinical data on the efficacy and safety of diabetic retinopathy treatments to facilitate management decisions and patient education strategies
  • Discuss strategies, including the use of telemedicine, for improving assessment and management of diabetic retinopathy in rural and underserved areas


Rishi P. Singh, MD

Rishi P. Singh, MD (Activity Chair)

Staff Surgeon
Cleveland Clinic Cole Eye Institute
Associate Professor of Ophthalmology
Lerner College of Medicine
Case Western Reserve University
Cleveland, OH

Barbara P. Yawn, MD, MSc, MPH

Barbara P. Yawn, MD, MSc, MPH (Moderator)

Chief Science Officer, COPD Foundation
Professor of Family and Community Health
University of Minnesota
Minneapolis, MN

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RME Collaborative. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.25 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.

Disclosures of Conflicts of Interest

The Postgraduate Institute for Medicine requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.


Rishi P. Singh, MD, has disclosed the following relationships: consultant for Alcon, Bausch + Lomb, Genentech, Inc., Novartis Pharmaceuticals, Regeneron Pharmaceuticals, Inc., and ZEISS; grant/research support from Aerie Pharmaceuticals, Inc., Apellis Pharmaceuticals, Inc., and Graybug Vision, Inc.

Barbara P. Yawn, MD, MSc, MPH, has disclosed the following relationships: consultant for AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis Pharmaceuticals, and Teva Pharmaceuticals.

Planners and Managers

The planners and managers from RME Collaborative and PIM have nothing to disclose.

Instructions for Participation and Credit

This activity is offered at no cost to participants. To receive CME/CE credit, participants must:

  1. Review the CME/CE information, including the learning objectives and disclosure statements.
  2. Complete the pre-test.
  3. Participate in the online activity.
  4. Complete the post-test and evaluation form.
A post-test score of 65% or higher is required to obtain credit. Your certificate will be made available for immediate download.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

© RME Collaborative, a division of Talem Health, LLC 2021. All Rights Reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Talem Health, LLC is prohibited.

Contact Information

For questions about the activity, please contact: RME Collaborative by phone, 800-913-9370 or email, info@talemhealth.com.

For questions about the accreditation of this activity, please visit https://www.pimed.com.